ArticleMolecular biology reports2025
A potential protective factor against renal Ischemia-reperfusion damage: D-carvone.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Molecular Targets and Biological Activities of Carvone: An Evidence-Graded Review.Molecules (Basel, Switzerland) · 2026Review
- Nephroprotective Effect of L-Carvone on a Mouse Model of LPS-Induced Sepsis-Associated Renal Injury via Regulation of TLR4/NF-κB/AP-1/IRF-3 and Nrf2/iNOS Molecular Signaling Cascades.Journal of Taibah University Medical Sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
aimIschemia-reperfusion (IR) injury-induced renal failure is a major cause of death and morbidity. Unfortunately, there is currently no proven protective therapy. The aim of the study is to investigate the protective effect of D-carvone against the renal ischemia-reperfusion (RIR) injury.
methodThe study was conducted with 24 male Wistar-Albino rats. Rats were divided into three groups: Sham, RIR, and RIR + D-carvone (20 mg/kg) intraperitoneally daily for 15 days. ELISA was used to measure the levels of Neutrophil Gelatinase-Associated Lipocalin (NGAL), Ischemia-Modified Albumin (IMA), Tumor Necrosis Factor-alpha (TNF-α), interleukin-1beta (IL-1β), and IL-10. Aebi's spectrophotometric method was used to measure the levels of Catalase (CAT), Malondialdehyde (MDA), Glutathione (Reduced Form) (GSH), and Myeloperoxidase (MPO). Oxidative Stress Index (OSI) was computed, and Total Antioxidant Status (TAS) and Total Oxidant Status (TOS) levels were also assessed. Nuclear Factor kappa-light-chain-enhancer of activated B cells (NFκB), caspase-3, and Microtubule-associated protein 1 A/1B-light chain 3B (LC3B) were quantified using immunohistochemical and histological methods.
resultsTNF-α, IL-6, IL-1β, NGAL, MDA, MPO, TOS, OSI, and IMA levels decreased significantly in the treatment group, while IL-10, TAS, GSH, and CAT levels increased. LC3B, NFκB, and Caspase-3 levels, which increased with RIR damage, decreased significantly in the treatment group. Mild congestion and necrosis were observed in the kidney tissues in the treatment group compared to the RIR group.
conclusionD-carvone decreases oxidative stress and protects against kidney damage by having anti-inflammatory, anti-apoptotic, and autophagy inhibitory actions against IR damage. Based on the results, D-carvone may be a potential protective agent in therapeutic settings.
Indexed as
Identifiers
40911249What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.